Design Therapeutics, Inc. (DSGN)

Market Cap	782.74M
Revenue (ttm)	n/a
Net Income (ttm)	-57.03M
Shares Out	55.78M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,575
Open	13.84
Previous Close	14
Day's Range	13.5 - 14.07
52-Week Range	9.61 - 26.3
Beta	n/a
Analysts	Buy
Price Target	27.13 (+98.5%)
Earnings Date	Nov 7, 2022

About DSGN

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromus...

• Industry: Biotechnology
• IPO Date: Mar 26, 2021
• CEO: João Siffert
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: DSGN

Analyst Forecast

According to 11 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 27.13, which is an increase of 98.46% from the latest price.

Price Target

$27.13

(98.46% upside)

Analyst Consensus: Buy